EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients



Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients



Anticancer Research 22(6B): 3701-3708



Background and Objectives: High-dose chemotherapy (HDC) with autologus PBPC-T has been reported to be effective in hematological and in selected solid malignancies. In this setting, infectious complications represent a relevant cause of morbidity.

(PDF emailed within 1 workday: $29.90)

Accession: 010616393

Download citation: RISBibTeXText



Related references

Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Research 22(6b): 3701-3708, 2003

Evaluation of infectious complications and immune recovery following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation in 148 breast cancer patients. Anticancer Research 22(6B): 3701-3708, November-December, 2002

High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT). Annals of Oncology 6 Suppl 4: 33-37, 1995

Tumor cell contamination of peripheral blood samples and peripheral blood progenitor cell separates in high risk patients with breast cancer treated by high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation. Onkologie 18(SUPPL 2): 102, 1995

Sequential high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation for breast cancer patients. Blood 90(10 SUPPL 1 PART 2): 401B, Nov 15, 1997

Infectious complications after autologous peripheral blood progenitor cell transplantation in breast cancer patients. European Journal of Cancer 37(Supplement 6): S111, October, 2001

Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer - follow up at 10 years. Experimental Oncology 29(2): 144-151, 2007

Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. International Journal of Hematology 79(1): 85-91, 2004

Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation. Journal of HematoTherapy & Stem Cell Research 9(1): 103-109, 2000

High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer. Medicina Clinica 109(20): 775-781, 1998

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 23(1): 27-33, 1999

The use of CD34+-selected PBPC after high-dose chemotherapy in breast cancer patients is associated with prolonged recovery time and increased infectious complications. Journal of HematoTherapy & Stem Cell Research 8(4): 387-391, 2000

The incidence of thrombotic and embolic events in controlled clinical trials of breast cancer patients undergoing high dose chemotherapy with the stamp I regimen and autologous peripheral blood progenitor cell transplantation. Blood 90(10 SUPPL 1 PART 1): 220A-221A, Nov 15, 1997

Infectious complications in women undergoing autologous peripheral blood progenitor cell transplantation for breast cancer. Blood 92(10 SUPPL 1 PART 1-2): 320B, Nov 15, 1998

Low incidence of infectious complications in patients undergoing high dose chemotherapy and autologous peripheral blood stem cell transplantation in a totally outpatient setting. Blood 90(10 SUPPL 1 PART 2): 371B, Nov 15, 1997